NEW YORK (GenomeWeb) – Comprehensive sequencing-based tumor profiling in high-risk pediatric cancer patients yields a clinically significant finding in the majority of cases, but only a few receive a matched drug as a result, according to a new study by researchers at Columbia University Medical Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.